Assenagon Asset Management S.A. bought a new position in Jounce Therapeutics Inc (NASDAQ:JNCE) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 47,991 shares of the company’s stock, valued at approximately $162,000. Assenagon Asset Management S.A. owned approximately 0.15% of Jounce Therapeutics as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Creative Planning bought a new position in shares of Jounce Therapeutics during the 3rd quarter valued at $143,000. BlackRock Inc. raised its holdings in shares of Jounce Therapeutics by 22.2% during the 2nd quarter. BlackRock Inc. now owns 1,394,905 shares of the company’s stock valued at $10,684,000 after purchasing an additional 253,120 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Jounce Therapeutics by 20.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 47,951 shares of the company’s stock valued at $368,000 after purchasing an additional 8,103 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Jounce Therapeutics by 91.6% during the 2nd quarter. Millennium Management LLC now owns 679,177 shares of the company’s stock valued at $5,202,000 after purchasing an additional 324,681 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Jounce Therapeutics during the 3rd quarter valued at $677,000. Institutional investors own 82.68% of the company’s stock.

A number of research analysts have recently weighed in on JNCE shares. Zacks Investment Research upgraded shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a report on Tuesday, January 15th. HC Wainwright set a $13.00 target price on shares of Jounce Therapeutics and gave the stock a “buy” rating in a report on Wednesday, November 14th. JPMorgan Chase & Co. downgraded shares of Jounce Therapeutics from a “neutral” rating to an “underweight” rating in a report on Tuesday, November 13th. Cowen reiterated a “hold” rating on shares of Jounce Therapeutics in a report on Tuesday, November 13th. Finally, Raymond James dropped their target price on shares of Jounce Therapeutics from $13.00 to $12.00 and set an “outperform” rating on the stock in a report on Tuesday, October 23rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $11.67.

Shares of JNCE opened at $4.22 on Friday. The firm has a market capitalization of $137.99 million, a P/E ratio of -7.40 and a beta of 3.80. Jounce Therapeutics Inc has a one year low of $2.66 and a one year high of $29.25.

Jounce Therapeutics (NASDAQ:JNCE) last announced its earnings results on Tuesday, November 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.11. The firm had revenue of $14.53 million for the quarter, compared to the consensus estimate of $12.80 million. Jounce Therapeutics had a negative net margin of 59.74% and a negative return on equity of 29.58%. On average, analysts expect that Jounce Therapeutics Inc will post -1.13 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2019/02/09/assenagon-asset-management-s-a-buys-shares-of-47991-jounce-therapeutics-inc-jnce.html.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

See Also: What is Net Asset Value (NAV)?

Want to see what other hedge funds are holding JNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jounce Therapeutics Inc (NASDAQ:JNCE).

Institutional Ownership by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.